The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review
Journal of Pain Research · 2023-03 · Volume 16 · 1017-1023
DOI: 10.2147/jpr.s395457 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pain Research, 2023-03. Verfasst von Juan Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCCIH NIH HHS.
Abstract (Originalsprache)
Fibromyalgia (FM) is a chronic pain sensitivity syndrome characterized by diffuse musculoskeletal pain and many other systemic manifestations. Low-dose naltrexone (LDN) has been increasingly used as an off-label treatment option in FM. However, current evidence on the safety and efficacy of LDN in patients with FM is not well known. To systematically assess the current evidence on the safety and efficacy of LDN use in the treatment of FM. A comprehensive bibliographic search was conducted on EBM Reviews - Cochrane Central Register of Controlled Trials, EBM Reviews - Cochrane Database of Systematic, Embase, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions and Scopus databases in September 2022. Inclusion criteria were articles that were published in English, focusing on clinical trials involving LDN for the treatment of FM. Two reviewers independently screened and extracted the data. A qualitative analysis was used due to the high methodological heterogeneity between studies. The electronic search produced 805 articles. After applying the inclusion criteria, 9 articles (one RCT, two case reports, two case series, and four pilot trials) were selected for evaluation. LDN intervention protocols, study designs, and follow-up periods were different among the included studies. Overall, LDN was found to be effective in the symptomatic management of FM, and of the 78% of included studies that evaluated for safety, no severe adverse events were reported. Proving the efficacy and safety of low-dose naltrexone is a future possibility based on current study data, but the level of scientific evidence is limited. Future well-designed trials with large sample sizes are required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
- KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea.
- Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL, 32224, USA.
- Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA.
ORCID-Profile: Juan Yang, Brent A Bauer
Förderung
- NCCIH NIH HHS
Zitieren
APA
Yang, J., Shin, K. M., Do, A., Bierle, D. M., Abu Dabrh, A. M., Yin, Z., Bauer, B. A., & Mohabbat, A. B. (2023). The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. Journal of Pain Research, Volume 16, 1017-1023. https://doi.org/10.2147/jpr.s395457
Vancouver
Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, et al. The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. Journal of Pain Research. 2023;Volume 16:1017-1023. doi:10.2147/jpr.s395457
BibTeX
@article{Yang2023,
author = {Yang, Juan and Shin, Kyung-Min and Do, Alex and Bierle, Dennis M and Abu Dabrh, Abd Moain and Yin, Ziying and Bauer, Brent A and Mohabbat, Arya B},
title = {The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review},
journal = {Journal of Pain Research},
year = {2023},
volume = {Volume 16},
pages = {1017--1023},
doi = {10.2147/jpr.s395457}
}
EUVIMED